Drug Trial Radar · NCT06434961
The Trial of SHR6508 in Secondary Hyperparathyroidism
Last checked: Nov 19, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
498
Actual
Start
Jun 14, 2024
Primary completion
Sep 29, 2025
Study completion Nov 11, 2025
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
Conditions
- Secondary Hyperparathyroidism
Interventions
SHR6508 plus oral placebo tabletsDrug
SHR6508 plus oral placebo tablets
Cinacalcet plus intravenous placeboDrug
Cinacalcet plus intravenous placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants to End of Study whose iPTH decreased by>30% from baselineTime frame: efficacy assessment period, defined as Week 20-27
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.